Bristol Myers Squibb & Co. (NYSE:BMY) on Wednesday said it would enroll additional patients in the ADEPT-2 Phase 3 study.

BMY shares are climbing with conviction. See the market dynamics here.

The ADEPT-2 study is a multicenter, randomized, double-blind, placebo-controlled trial assessing the safety and efficacy of Cobenfy in subjects with psychosis associated with Alzheimer’s disease dementia.

The study is designed to evaluate the primary endpoint of changes in the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score and the key secondary endpoint of Clinical Global Impression-Severity (CGI-S), with additional assessments on safety and tolerability of Cobenfy compared to placebo.

Also Read: Bayer Stroke Drug Hits Trial Goals, Analyst Sees Positive Data Readout From Bristol Myers’ Milvexian After Failed Study

What is Cobenfy?

Cobenfy is currently approved for schizophrenia in adults.

Following a thorough blinded review of the ADEPT-2 study data, the company identified irregularities due to clinical trial execution at a small number of study sites.

With these findings, before the database ...